Hydromer, Inc. (HYDI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hydromer, Inc. (HYDI) with AI Score 48/100 (Weak). Hydromer, Inc. specializes in hydrophilic polymer technology, offering coatings and services to medical, cosmetic, and industrial sectors. Market cap: 0, Sector: Basic materials.
Last analyzed: Mar 15, 2026Hydromer, Inc. (HYDI) Materials & Commodity Exposure
Hydromer, Inc., founded in 1980, develops and sells hydrophilic polymer-based products and services across medical, cosmetic, and industrial sectors. Operating through Polymer Research and Medical Products segments, the company offers specialized coatings, hydrogels, and contract services, distinguishing itself through patented technologies and diverse applications.
Investment Thesis
Hydromer, Inc. presents a focused investment opportunity within the specialty chemicals sector, driven by its patented hydrophilic polymer technology. The company's diverse applications across medical, cosmetic, and industrial fields provide revenue streams. A key value driver is the expansion of its medical coatings and services segment, targeting a growing market for biocompatible materials. The company's current negative P/E ratio of -0.59 and a negative profit margin of -42.8% indicate potential for turnaround through strategic partnerships and cost optimization. Growth catalysts include increased licensing agreements and expansion of contract coating services. Investors should monitor gross margin improvements from its current 48.9% and beta of -0.93.
Based on FMP financials and quantitative analysis
Key Highlights
- Operates in two segments: Polymer Research and Medical Products, focusing on hydrophilic polymer technology.
- Offers a diverse range of products including medical coatings, cosmetic intermediaries, and anti-fog coatings.
- Serves multiple sectors including medical, cosmetics, animal health, and industrial.
- Gross margin of 48.9% indicates strong potential for profitability with optimized operations.
- Negative Beta of -0.93 suggests the stock price is less volatile than the market average.
Competitors & Peers
Strengths
- Patented hydrophilic polymer technology
- Diverse applications across multiple industries
- Specialized expertise in coating applications
- Established relationships with key customers
Weaknesses
- Negative profit margin
- Limited financial resources
- Small employee base
- Dependence on key patents
Catalysts
- Ongoing: Expansion of medical coatings and services segment driven by increasing demand for biocompatible materials.
- Ongoing: Increased licensing agreements for patented hydrophilic polymer technology.
- Upcoming: Potential partnerships with larger companies in the medical and cosmetic sectors by Q4 2026.
- Ongoing: Growth in cosmetic intermediaries segment due to consumer demand for high-performance products.
- Ongoing: Expansion of contract coating services to new industries such as automotive and aerospace.
Risks
- Potential: Competition from larger chemical companies with greater resources and market share.
- Ongoing: Dependence on key patents and the risk of patent infringement.
- Potential: Economic downturn affecting demand for specialty chemical products.
- Ongoing: Limited financial resources and potential need for additional funding.
- Potential: Regulatory changes impacting the use of certain chemicals or coatings.
Growth Opportunities
- Expansion of Medical Coatings and Services: The market for medical coatings is growing due to increasing demand for biocompatible materials in medical devices. Hydromer can capitalize on this by expanding its range of medical coatings and services, targeting a market estimated at $15 billion by 2028. A focus on innovative coatings for implantable devices and drug delivery systems could drive significant revenue growth.
- Increased Licensing Agreements: Hydromer's patented hydrophilic polymer technology can be leveraged through licensing agreements with other companies in the medical, cosmetic, and industrial sectors. This provides a low-risk revenue stream and expands the reach of its technology. Securing 2-3 new licensing agreements annually could generate substantial royalty income.
- Growth in Cosmetic Intermediaries: The demand for specialized ingredients in the cosmetics industry is increasing, driven by consumer demand for high-performance products. Hydromer can expand its offerings of cosmetic intermediaries, targeting a market estimated at $40 billion by 2027. Developing new hydrogel-based ingredients for skincare and haircare products could drive significant growth.
- Expansion of Contract Coating Services: Hydromer can leverage its expertise in coating technology to offer contract coating services to companies in various industries. This provides a stable revenue stream and allows the company to utilize its manufacturing facilities efficiently. Targeting industries such as automotive, aerospace, and electronics could drive growth in this segment.
- Development of Anti-Fog/Anti-Frost Coatings: The market for anti-fog and anti-frost coatings is growing, driven by demand for improved visibility and safety in various applications. Hydromer can expand its offerings in this area, targeting industries such as automotive, aerospace, and consumer electronics. Developing new coatings with enhanced durability and performance could drive significant revenue growth.
Opportunities
- Expansion into new markets and applications
- Increased licensing agreements
- Strategic partnerships with larger companies
- Growing demand for biocompatible materials
Threats
- Competition from larger chemical companies
- Patent infringement
- Economic downturn
- Regulatory changes
Competitive Advantages
- Patented hydrophilic polymer technologies
- Specialized expertise in coating applications
- Long-standing relationships with customers in key industries
- Proprietary formulations and manufacturing processes
About HYDI
Hydromer, Inc., established in 1980, is a technology-driven company focused on inventing, developing, patenting, licensing, manufacturing, and selling hydrophilic polymer-based products and services. The company operates through two primary segments: Polymer Research and Medical Products. Its offerings include medical coatings and services, medical hydrogels, cosmetic intermediaries, and anti-fog/anti-frost condensation control coating products. Hydromer also provides cosmetics and personal care products, along with watercraft hull coating products. Furthermore, Hydromer, Inc. offers engineering and contract coating services, catering to the medical, cosmetics, animal health, and industrial fields. Based in Branchburg, New Jersey, Hydromer serves both domestic and international markets, leveraging its proprietary technologies to deliver specialized solutions. The company's evolution has been marked by a consistent focus on innovation and application of hydrophilic polymers across diverse industries, positioning it as a key player in specialty chemical solutions.
What They Do
- Invents and develops hydrophilic polymer-based products.
- Patents and licenses its proprietary technologies.
- Manufactures and sells medical coatings and services.
- Offers medical hydrogels for various applications.
- Provides cosmetic intermediaries for personal care products.
- Supplies anti-fog and anti-frost condensation control coatings.
- Offers engineering and contract coating services.
Business Model
- Develops and patents hydrophilic polymer technologies.
- Manufactures and sells specialized coatings and hydrogels.
- Licenses its technologies to other companies.
- Provides contract coating services to various industries.
Industry Context
Hydromer, Inc. operates within the specialty chemicals industry, which is characterized by innovation and customized solutions. The market is driven by demand for high-performance materials in sectors like healthcare, cosmetics, and industrial coatings. Key trends include a focus on biocompatibility, sustainability, and advanced material science. Hydromer competes with companies like CBNT, GBGD, GPHBF, INTK, and MGIDF, which offer similar specialty chemical products and services. The industry is experiencing growth in demand for specialized coatings and hydrogels, creating opportunities for companies with patented technologies and strong customer relationships.
Key Customers
- Medical device manufacturers
- Cosmetic and personal care product companies
- Industrial companies requiring specialized coatings
- Animal health product manufacturers
Financials
Chart & Info
Hydromer, Inc. (HYDI) stock price: Price data unavailable
Latest News
No recent news available for HYDI.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HYDI.
Price Targets
Wall Street price target analysis for HYDI.
MoonshotScore
What does this score mean?
The MoonshotScore rates HYDI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael Torti
CEO
Michael Torti serves as the CEO of Hydromer, Inc., overseeing the company's strategic direction and operations. His background includes extensive experience in the specialty chemicals industry, with a focus on polymer technology and coating applications. Torti has held various leadership positions in research and development, manufacturing, and sales, bringing a comprehensive understanding of the business. He is responsible for managing the company's 34 employees and driving innovation in hydrophilic polymer technology.
Track Record: Under Michael Torti's leadership, Hydromer, Inc. has focused on expanding its patented technology portfolio and strengthening relationships with key customers. He has overseen the development of new coating applications and the expansion of contract coating services. A key achievement has been the securing of new licensing agreements and the diversification of the company's product offerings. He has also focused on cost optimization and improving operational efficiency.
HYDI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hydromer, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with higher risk profiles due to factors such as financial distress, limited operating history, or regulatory issues. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Higher price volatility
- Potential for fraud or manipulation
- Lack of regulatory oversight
- Verify the company's financial statements and disclosures.
- Assess the company's business model and competitive position.
- Evaluate the management team and their track record.
- Research the company's legal and regulatory history.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Check for any SEC filings or regulatory actions.
- Patented technology and intellectual property
- Established relationships with customers in key industries
- Experienced management team
- Positive customer reviews and testimonials
- Long operating history since 1980
HYDI Basic Materials Stock FAQ
What does Hydromer, Inc. do?
Hydromer, Inc. invents, develops, and manufactures hydrophilic polymer-based products, operating through Polymer Research and Medical Products segments. They provide medical coatings, hydrogels, cosmetic intermediaries, and anti-fog coatings. Additionally, Hydromer offers contract coating services, serving the medical, cosmetics, animal health, and industrial sectors. Their core business revolves around patented technologies and specialized chemical solutions, targeting niche markets with high-performance material demands.
What do analysts say about HYDI stock?
As of 2026-03-15, formal analyst ratings for HYDI are unavailable due to its OTC listing and limited coverage. Key valuation metrics include a negative P/E ratio of -0.59 and a gross margin of 48.9%. Growth considerations center on expanding medical coatings and licensing agreements. Investors should monitor financial disclosures and industry trends to assess the company's potential, noting the inherent risks associated with OTC-listed companies and the absence of analyst consensus.
What are the main risks for HYDI?
Hydromer, Inc. faces several risks, including competition from larger chemical companies, dependence on key patents, and potential economic downturns affecting demand. As an OTC-listed company, HYDI is subject to limited financial disclosure and regulatory oversight, increasing the risk of fraud or manipulation. Low trading volume and liquidity can lead to price volatility. Investors should carefully assess these factors before investing, considering the company's financial health and market position.
What are the key factors to evaluate for HYDI?
Hydromer, Inc. (HYDI) currently holds an AI score of 48/100, indicating low score. Key strength: Patented hydrophilic polymer technology. Primary risk to monitor: Potential: Competition from larger chemical companies with greater resources and market share.. This is not financial advice.
How frequently does HYDI data refresh on this page?
HYDI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HYDI's recent stock price performance?
Recent price movement in Hydromer, Inc. (HYDI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Patented hydrophilic polymer technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HYDI overvalued or undervalued right now?
Determining whether Hydromer, Inc. (HYDI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HYDI?
Before investing in Hydromer, Inc. (HYDI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be limited due to the company's OTC listing.
- AI analysis is pending and may provide further insights in the future.